journal article·2025-01-01Open access

A generic cell-based biosensor converts bacterial infection signals into chemoattractants for immune cells

Sushobhan Sarker, Mario Köster, Omkar Desai, Muhammad Imran Rahim, Sabrina Herrmann, Sara Behme, Meike Stiesch, Hansjörg Hauser, Dagmar Wirth

Biofabrication· Volume 17· Issue 1

Abstract

Abstract Bacterial infection is a major challenge to human health. Although various potent antibiotics have emerged in recent decades, current challenges arise from the increasing number of multi-drug-resistant species. Infections associated with implants represent a particular challenge because they are usually diagnosed at an advanced stage and are difficult to treat with antibiotics owing to the formation of protective biofilms. In this study, we designed and explored a synthetic biology-inspired cell-based biosensor/actor for the detection and counteraction of bacterial infections. The system is generic, as it senses diverse types of infections and acts by enhancing the endogenous immune system. This strategy is based on genetically engineered sensor/actor cells that can sense type I interferons (IFNs), which are released by immune cells at the early stages of infection. IFN signalling activates a synthetic circuit to induce reporter genes with a sensitivity of only 5 pg ml−1 of IFN and leads to a therapeutic protein output of 100 ng ml−1, resulting in theranostic cells that can visualize and fight infections. Robustness and resilience were achieved by implementing a positive feedback loop. We showed that diverse gram-positive and gram-negative implant-associated pathogenic bacteria activate the cascade in co-culture systems in a dose-dependent manner. Finally, we showed that this system can be used to secrete chemoattractants that facilitate the infiltration of immune cells in response to bacterial triggers. Together, the system is not only universal to bacterial infections, but also hypersensitive, allowing the sensing of infections at initial stages.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Virus-based gene therapy research · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. The epidemiology of peri-implantitis10.1111/j.1600-0501.2012.02541.x ↗
2. Treatment of infections associated with surgical implants10.1056/NEJMra035415 ↗
3. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics10.1038/s41579-024-01054-w ↗
4. Neurotoxic effects associated with antibiotic use: management considerations10.1111/j.1365-2125.2011.03991.x ↗
5. Recent strategies to combat infections from biofilm-forming bacteria on orthopaedic implants10.3390/ijms221910243 ↗
6. Implant materials and prosthetic joint infection: the battle with the biofilm10.1302/2058-5241.4.180095 ↗
7. Surface treatment strategies to combat implant-related infection from the beginning10.1016/j.jot.2018.09.001 ↗
8. Recent developments in controlled release of antibiotics10.2174/1381612824666180315094947 ↗
9. Coatings as the useful drug delivery system for the prevention of implant-related infections10.1186/s13018-018-0930-y ↗
10. Pathogen recognition and innate immunity10.1016/j.cell.2006.02.015 ↗
11. Constitutive immune mechanisms: mediators of host defence and immune regulation10.1038/s41577-020-0391-5 ↗
12. Pattern recognition receptors in health and diseases10.1038/s41392-021-00687-0 ↗
13. Innate immune detection of microbial nucleic acids10.1016/j.tim.2013.04.004 ↗
14. Bacterial immune evasion through manipulation of host inhibitory immune signaling10.1371/journal.ppat.1004644 ↗
15. CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex10.1371/journal.ppat.1002597 ↗
16. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens10.1016/j.cell.2006.01.034 ↗
17. From synthetic biology to human therapy: engineered mammalian cells10.1016/j.copbio.2019.02.023 ↗
18. Synthetic gene circuits for the detection, elimination and prevention of disease10.1038/s41551-018-0215-0 ↗
19. Engineering mammalian cells for disease diagnosis and treatment10.1016/j.copbio.2018.08.008 ↗
20. Type I interferons in infectious disease10.1038/nri3787 ↗
21. Type I interferons in bacterial infections: a balancing act10.3389/fimmu.2016.00652 ↗
22. The roles of type I interferon in bacterial infection10.1016/j.chom.2016.05.016 ↗
23. Interferons: tug of war between bacteria and their host10.3389/fcimb.2021.624094 ↗
24. IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation10.1038/s41467-019-10903-9 ↗
25. Antiviral Innate Immunity: introduction
26. The isolation and characterization of murine macrophages10.1002/0471142735.im1401s83 ↗
27. Synthetic rewiring and boosting type I interferon responses for visualization and counteracting viral infections10.1093/nar/gkaa961 ↗
28. Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes10.1006/mthe.2001.0480 ↗
29. Effect of titanium implants along with silver ions and tetracycline on type I interferon-beta expression during implant-related infections in co-culture and mouse model10.3389/fbioe.2023.1227148 ↗
30. Bacterial-specific induction of inflammatory cytokines significantly decreases upon dual species infections of implant materials with periodontal pathogens in a mouse model10.3390/biomedicines10020286 ↗
31. Negative regulation of type I IFN signaling10.1002/JLB.2MIR0817-342R ↗
32. Mimiviruses and the human interferon system: viral evasion of classical antiviral activities, but inhibition by a novel interferon-beta regulated immunomodulatory pathway10.1089/jir.2016.0097 ↗
33. Type I interferon production of plasmacytoid dendritic cells under control10.3390/ijms22084190 ↗
34. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies10.1002/stem.433 ↗
35. Regulation of type I interferon responses10.1038/nri3581 ↗
36. The impact of the interferon/TNF-related apoptosis-inducing ligand signaling axis on disease progression in respiratory viral infection and beyond10.3389/fimmu.2017.00313 ↗
37. Ubiquitination network in the type I IFN-induced antiviral signaling pathway10.1002/eji.202350384 ↗
38. Evaluation of the inflammatory potential of implant materials in a mouse model by bioluminescent imaging of intravenously injected bone marrow cells10.1002/jbm.a.35758 ↗
39. Activity of abundant antimicrobials of the human airway10.1165/ajrcmb.20.5.3572 ↗
40. Recent antibacterial carbohydrate-based prodrugs, drugs and delivery systems to overcome antimicrobial resistance10.1016/j.cbpa.2023.102419 ↗
41. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid10.1152/ajplung.2000.279.5.L799 ↗
42. Nonclassical antagonism between human lysozyme and AMPs against Pseudomonas aeruginosa10.1002/2211-5463.13094 ↗
43. Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins10.1038/s41598-022-05361-1 ↗
44. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus10.1128/AAC.01625-09 ↗
45. Combination effect of engineered endolysin EC340 with antibiotics10.3389/fmicb.2022.821936 ↗
46. Microencapsulation-based cell therapies10.1007/s00018-022-04369-0 ↗
47. Synthetic Gene Circuits for regulation of next-generation cell-based therapeutics10.1002/advs.202309088 ↗
48. STING signaling and sterile inflammation10.3389/fimmu.2021.753789 ↗
49. BioLogic gates enable logical transcription control in mammalian cells10.1002/bit.20142 ↗
50. Combinatorial protein dimerization enables precise multi-input synthetic computations10.1038/s41589-023-01281-x ↗
51. Theranostic cells: emerging clinical applications of synthetic biology10.1038/s41576-021-00383-3 ↗